Short answer
Larimar Therapeutics, Inc. (LRMR) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$48M
- −207.8% YoY · −82.2% QoQ
- EPS (diluted)
- −$0.63
- −162.5% YoY · −53.7% QoQ
Source: XBRL data from the Larimar Therapeutics, Inc. (LRMR) Q3 2025 10-Q on SEC EDGAR. USD.
Larimar Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk factors provided in the submitted excerpt
- No newly added, updated, regulatory, operational, competitive, or financial risks identifiable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Larimar Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.